VI: Data Collection
The criteria examined was evidence that proved that matching or any types of donors would help increase the rate of survival, and
decrease the rate of relapse.
Articles used:
Runzhe Chen, Jos L Campbell, and
Baoan Chen. ​Prophylaxis and
treatment of acute lymphoblastic
leukemia relapse after allogeneic
hematopoietic stem cell
transplantation. ​Published: 10
February ​2015.
Results of the study:
1. “Protection against relapse
can be increased using
unrelated donors, cord
blood donors, or
HLA-matched
donors.​17​,​37​,​40​,​51​ To
improve outcomes and
decrease the risk of
relapse, younger donors
should also be sought ​52​”
(Chen, 2015).
2. “The occurrence of acute
GVHD is affected by the
degree of HLA matching
and the type of donor. The
development of chronic
GVHD after DLIs is
associated with the highest
rate of response to DLI and
higher survival rates ​68​”
(Chen, 2015).
3. “The GVL effect in ALL is
probably one of the most
potent strategies with
curative potential, and DLI
Comparison:
● All articles were related to hematopoietic
stem cell transplantation.
● All had evidence or were inferring that
HLA-matching related was the best donor
option.
● All came to the conclusion that various types
of donors are needed.
● All compared different donor types on a
population in the data.
● Bejanyan and Solh’s articles had evidence
based on the same case study (CIBMTR).
● All discussed the survival rates and impacts
of a relapse on the patient.
● Articles mentioned Donor Lymphocyte
Infusions as a method to prevent future
relapses.
● Discussed both common cases of Leukemia
(ALL and AML).
Relapses are associated with GVHD within
the patient.
 is an attractive option for
prophylaxis against relapse
of ALL after
transplantation ​14​” (Chen,
2015).

Nelli Bejanyan, Daniel J.

Weisdorf, Brent R. Logan, Hai-Lin
Wang, Steven M. Devine, Marcos
de Lima, Donald W. Bunjes, and
Mei-Jie Zhang. ​Survival of AML
patients relapsing after
allogeneic hematopoietic cell
transplantation: a CIBMTR
study. ​Published: March 2015.

M Solh, X Zhang, K Connor, S
Brown, S R Solomon, L E Morris,
H K Holland, and A Bashey.
Post-relapse survival after
haploidentical transplantation vs
matched-related or
matched-unrelated
hematopoietic cell
transplantation. ​Published online:
21 March 2016.
The above data was provided by
“Survival of AML patients
relapsing after allogeneic
hematopoietic cell transplantation:
a CIBMTR study” by Nelli
Bejanyan, et al.
5. “​...patients with relapsed acute
myelogeneous leukemia after
mismatched-unrelated or double
cord transplantation had a worse
PRS than recipients of a matched
sibling or matched-unrelated HCT
8​” (Solh, 2016).
 The above graphs were provided
by “​Post-relapse survival after
haploidentical transplantation vs
matched-related or
matched-unrelated hematopoietic
cell transplantation” by Melhem
M. Solh, et al.

6. “...immune recovery remains

delayed, and infections remain a
Orly R. Klein, Allen R. Chen, leading cause of mortality in this
Christopher Gamper, David Loeb,
Elias Zambidis, Nicolas Llosa,
Jeffrey Huo, Amy E. Dezern,
Diana Steppan, Nancy Robey,
Mary Jo Holuba, Kenneth R.
Cooke, Heather J. Symons.
Alternative donor hematopoietic
stem cell transplantation with
post-transplantation
cyclophosphamide for
nonmalignant disorders.
Published: May 2016.
group of patients [​31​-​33​]. This is
further evidence that expanding
the donor pool with alternative
bone marrow donors, including
both mismatched unrelated and
related HLA-haploidentical
donors, is greatly needed” (Klein,
2016).
7. “Given that HLA-matched
donors can only be found for 50%
of patients (and for less than 20%
of African American patients),
there is tremendous need to
develop novel strategies for all
patients, especially racial
minorities [​3​]” (Klein, 2016).
8. “There is great success using
HLA-matched related donors for
these patients; however, the use of
alternative donors has been
associated with increased graft
failure, graft versus host disease
(GVHD), and transplant-related
mortality (TRM)” (Klein, 2016).